Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib + trastuzumab + chemotherapy as neoadjuvant therapy for HER2-positive breast cancer
ChiCTR2100051468Phase 3Recruiting
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
- Start
- Sep 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of pyrotinib and trastuzumab in breast cancer, sponsored by The Affiliated Hospital of Xuzhou Medical University. Primary endpoint: Pathological complete remission. Started Sep 2021; status: recruiting.
02
Drugs
pyrotinibtrastuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2100051468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100051468.